The TGA is weighing up Australia’s first potential respiratory syncytial virus vaccine, while the US regulator has given preliminary approval to two vaccine candidates, as the RSV vaccine race tightens.  

GSK Australia lodged applied to the TGA for approval of protein-based vaccine Arexvy this year, following positive results from its phase III clinical trial.